Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT06716580
Official study title

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

Study summary

This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay

Ask AI to explain this study
Start here

Key things to know

Main goalScreening

This describes the study’s primary purpose.

What is being studiedCirculating Tumor DNA (ctDNA) Assay

The study team can explain what participation involves.

Who it may be forEGFR

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 15, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?6 U.S. locations

Locations may change over time.

Who runs it?Dana-Farber Cancer Institute

Study sponsor

01
Study overview

What this study is about

Purpose
Screening
Study type
Interventional
Phase
Not applicable
Sponsor
Dana-Farber Cancer Institute
Interventions being studied
Device: Circulating Tumor DNA (ctDNA) Assay
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Biomarkers
EGFR→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • (Aims 1, 2, and 3) for Group 1 (50 through 80 years of age):
  • Non-tobacco using (currently)
  • Self-identify as East Asian (including Southeast Asian) or Hispanic/Latinx.
  • East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, Malaysian
  • Southeast Asian includes those who self-identify as Cambodian, Thai, Vietnamese, Filipino
  • Latinx includes those who self-identify as a person of Central or South American and the Caribbean including, Cuban, Puerto Rican, and Dominican culture or origin, excluding individuals originating from Spain
  • Aims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean
  • Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish. Inclusion Criteria (Aims 1, 2, and 3) for Group 2 (40 through 49 years of age):
  • Non-tobacco using (currently)
  • Self-identify as East Asian (including Southeast Asian) or Latinx, if any of the following criteria are met:
  • Family history of EGFR positive LC L858R or exon 19
  • Personal history of remote cancer that is not LC or other thoracic malignancies, including thymoma, thymic carcinoma, or sarcoma, as long as it was resolved over 5 years ago
  • History of TB, asthma requiring daily inhaled corticosteroids or chronic bronchitis
  • Symptoms of lung cancer for the past month, including hemoptysis, unexplained weight loss, voice hoarseness, cough or worsening cough, dyspnea or worsening dyspnea
  • Excluding individuals who concurrently present with fever, covid/influenza/RSV/adenovirus infection, runny nose, sore throat, productive cough with green or yellow sputum
  • Aims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean
  • Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.
Reasons someone may not be able to joinExclusion criteria
  • (Aims 1, 2, and 3) for Groups 1 and 2:
  • Having had a chest CT scan in the last 3 years or having an anticipated chest CT scan during the enrollment period.
  • Having a current cancer or history of cancer within the last 5 years, excluding localized non-melanoma skin cancer and breast ductal carcinoma in situ.
  • More than 400 lifetime cigarettes (i.e., 20 packs) of smoking or tobacco use
  • Adults unable to provide informed consent
  • Individuals \<40 years of age
  • Prisoners
  • Pregnant women
  • Personal diagnosis of lung cancer
  • Not able to be compliant with study requirements

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Beth Israel Deaconess Medical CenterBoston, Massachusetts
  • Dana-Farber Cancer InstituteBoston, Massachusetts
  • Massachusetts General HospitalBoston, Massachusetts
  • Dana-Farber Cancer Institute at Steward St. Elizabeth'sBrighton, Massachusetts
  • Dana-Farber Cancer Instiute Merrimack ValleyMethuen, Massachusetts
  • Dana-Farber Cancer Institute South ShoreSouth Weymouth, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 15, 2026. Always confirm current availability with the study team.

View original record ↗